LivaNova PLC (LIVN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

LivaNova PLC (LIVN) Healthcare & Pipeline Overview

LivaNova PLC is a medical device company specializing in cardiopulmonary, neuromodulation, and advanced circulatory support solutions. With a global presence and a focus on innovative therapies for epilepsy, depression, heart failure, and other critical conditions, LivaNova serves hospitals, physicians, and healthcare providers through direct sales and distribution networks.

What Is the Investment Thesis for LIVN?

LivaNova PLC presents a compelling investment case driven by its established position in the medical device industry and its focus on innovative therapeutic solutions. With a market capitalization of $4.30B and a profit margin of 7.5%, the company demonstrates financial stability. Key value drivers include the continued adoption of VNS Therapy for neurological disorders and the expansion of its cardiopulmonary product line. Growth catalysts include the potential approval and commercialization of the VITARIA System for heart failure and strategic collaborations to enhance its product offerings. However, potential risks include regulatory hurdles, competition from other medical device manufacturers, and the successful integration of new technologies.

Based on FMP financials and quantitative analysis

LIVN Key Highlights

Market capitalization of $4.30B, reflecting investor confidence in LivaNova's market position.

• P/E ratio of 36.69, indicating a premium valuation based on earnings expectations.
• Gross margin of 67.5%, showcasing strong pricing power and efficient cost management.
• Profit margin of 7.5%, demonstrating profitability in the competitive medical device market.
• Beta of 0.97, suggesting moderate volatility relative to the overall market.

Who Are LIVN's Competitors?

LIVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LIVN's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Established global presence with a strong distribution network.
• Proprietary VNS Therapy technology for neurological disorders.
• Research collaboration with Verily to capture clinical biomarkers.

What Are LIVN's Weaknesses?

Reliance on a limited number of key products.

• Exposure to regulatory risks and product recalls.
• Competition from larger medical device manufacturers.
• Dependence on third-party distributors in certain markets.

What Could Drive LIVN Stock Higher?

Potential regulatory approvals for new indications of VNS Therapy.

• Clinical trial results for the VITARIA System in heart failure patients.
• Expansion of strategic partnerships and collaborations.
• Increasing adoption of LivaNova's products in emerging markets.

What Are the Key Risks for LIVN?

Product liability claims and litigation related to medical devices.

• Regulatory hurdles and delays in product approvals.
• Intense competition from established medical device companies.
• Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for LIVN?

• Expansion of Neuromodulation Segment: LivaNova has the opportunity to expand its Neuromodulation segment by increasing the adoption of VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression. LivaNova's competitive advantage lies in its established VNS Therapy System and ongoing clinical trials to expand its applications.
• Commercialization of VITARIA System: The successful development and commercialization of the VITARIA System for treating heart failure through VNS represents a significant growth opportunity for LivaNova. The global heart failure market is expected to grow substantially, driven by an aging population and increasing prevalence of cardiovascular diseases. LivaNova's VITARIA System has the potential to address an unmet need in heart failure treatment and generate substantial revenue.
• Strategic Partnerships and Collaborations: LivaNova can pursue strategic partnerships and collaborations to enhance its product offerings and expand its market reach. Collaborating with technology companies, research institutions, and other medical device manufacturers can accelerate innovation and provide access to new markets. The company's existing research collaboration with Verily to capture clinical biomarkers of depression exemplifies this strategy.
• Geographic Expansion: LivaNova has the opportunity to expand its geographic presence in emerging markets, where healthcare spending is increasing and access to advanced medical technologies is improving. Focusing on key markets in Asia-Pacific, Latin America, and the Middle East can drive revenue growth and diversify the company's revenue streams. Adapting its product offerings to meet the specific needs of these markets will be crucial for success.
• Advancements in Cardiopulmonary Products: LivaNova can continue to innovate and develop advanced cardiopulmonary products to improve patient outcomes during cardiac surgery. The global market for cardiopulmonary devices is expected to grow, driven by increasing demand for minimally invasive surgical procedures and advancements in perfusion technologies. LivaNova's focus on developing innovative oxygenators, heart-lung machines, and autotransfusion systems can drive growth in this segment.

What Are LIVN's Competitive Advantages?

• Proprietary VNS Therapy technology for treating neurological disorders.
• Established relationships with hospitals and healthcare providers.
• Global distribution network for reaching diverse markets.
• Strong brand reputation for quality and innovation in medical devices.

What Does LIVN Do?

Founded in 1987 and headquartered in London, United Kingdom, LivaNova PLC has evolved into a prominent medical device company with a global footprint. The company operates through three key segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment provides essential products such as oxygenators and heart-lung machines used during cardiac surgery. The Neuromodulation segment focuses on VNS (Vagus Nerve Stimulation) Therapy System, an implantable device for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea, and is developing the VITARIA System for heart failure. The Advanced Circulatory Support segment offers temporary life support solutions. LivaNova serves a diverse customer base, including perfusionists, neurologists, neurosurgeons, hospitals, medical institutions, and healthcare providers, selling its products through direct sales representatives and independent distributors. The company also has a research collaboration with Verily to capture clinical biomarkers of depression, highlighting its commitment to innovation and improving patient outcomes.

What Products and Services Does LIVN Offer?

• Designs, develops, manufactures, and sells therapeutic solutions.
• Offers cardiopulmonary products like oxygenators and heart-lung machines.
• Provides VNS Therapy System for drug-resistant epilepsy and depression.
• Develops the VITARIA System for treating heart failure.
• Offers temporary life support products for cardiopulmonary and respiratory support.
• Sells products through direct sales representatives and independent distributors.

How Does LIVN Make Money?

• Develops and manufactures medical devices across three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support.
• Sells products directly to hospitals, medical institutions, and healthcare providers.
• Utilizes a network of independent distributors to expand market reach.
• Generates revenue through the sale of medical devices and related services.

What Industry Does LIVN Operate In?

LivaNova PLC operates within the medical device industry, a sector characterized by continuous innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. LivaNova competes with other medical device manufacturers, including CDTX: Cidara Therapeutics, Inc., SRRK: Scholar Rock Holding Corporation, and LEGN: Legend Biotech Corporation, striving to differentiate itself through product innovation, strategic partnerships, and global market expansion.

Who Are LIVN's Key Customers?

• Perfusionists who use cardiopulmonary products during cardiac surgery.
• Neurologists and neurosurgeons who prescribe VNS Therapy for epilepsy and depression.
• Hospitals and medical institutions that purchase medical devices for various therapeutic applications.
• Healthcare providers who utilize temporary life support products for critical care.

LivaNova PLC (LIVN) Valuation Context

Valued at $4.30B, LIVN is classified as a mid-cap stock. Relative to its peer group, LIVN's quantitative score of 59/100 is roughly in line with the peer average of 55/100.

LIVN Revenue & Earnings Trend

In Q2 2026, LIVN generated $390.6M in top-line revenue, marking a sequential increase of 7.8%. The company recorded net income of $108.6M, with diluted EPS of $1.93. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, LIVN averaged $0.85 in diluted EPS.

Company Profile

LivaNova PLC operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Vladimir A. Makatsaria. LIVN has traded publicly since 2015.

Return on equity for LivaNova PLC stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.3%, showing how much profit it generates from its asset base. LIVN trades at a trailing price-to-earnings ratio of 41.57, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.4%, the inverse of the P/E and a quick read on earnings relative to price.

LivaNova PLC's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.36 places it in the grey zone, a middle ground that warrants monitoring.

LivaNova PLC has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 16.2% above estimates on average.

Wall Street analysts project LivaNova PLC revenue of about $1.52B for fiscal 2026, with EPS near $4.34. The estimate reflects 6 contributing analysts.

LIVN Financials

LIVN Latest News

No recent news available for LIVN.

LIVN Analyst Consensus

LIVN MoonshotScore

LivaNova PLC Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources